Evidence map›Paper›PMID 41799688›Full record

ArticleJournal of the Endocrine Society2026

Prediction of distant metastases at diagnosis in medullary thyroid cancer: combining calcitonin with lymph node imaging.

Leonoor E Schonebaum, Hossein Razaghi Siahroudi, Layal Chaker, Sjoerd A A van den Berg, Tessa M van Ginhoven, Robin P Peeters, W Edward Visser

Abstract read
In one paragraph

Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Leonoor E SchonebaumAcademic Center for Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.ORCID https://orcid.org/0009-0001-7777-8609
Hossein Razaghi SiahroudiAcademic Center for Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.
Layal ChakerAcademic Center for Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.ORCID https://orcid.org/0000-0001-7855-5418
Sjoerd A A van den BergDiagnostic Laboratory for Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.ORCID https://orcid.org/0000-0001-5937-7505
Tessa M van GinhovenAcademic Center for Thyroid Disease, Department of Oncological Surgery, Erasmus Medical Center Cancer Center, Rotterdam 3015 CE, The Netherlands.ORCID https://orcid.org/0000-0002-9365-4892
Robin P PeetersAcademic Center for Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.ORCID https://orcid.org/0000-0001-7732-9371
W Edward VisserAcademic Center for Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 CE, The Netherlands.ORCID https://orcid.org/0000-0002-5248-863X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Current guidelines recommend performing preoperative additional imaging in patients with medullary thyroid cancer (MTC) when calcitonin levels exceed 500 pg/mL to detect distant metastases (M1). However, this recommendation is based on limited evidence. Whether this is the optimal cutoff, including other diagnostic characteristics, has only been partially evaluated in research. Objective: The aims of this study were to evaluate the current calcitonin-driven recommendation and to investigate whether other diagnostic characteristics can be added to improve prediction of M1 disease at diagnosis. Methods: Adult MTC patients treated in a tertiary care hospital between 1984 and 2023 with a preoperative calcitonin measurement were retrospectively collected. M1 disease was detected by preoperative imaging or biopsy. Logistic regression was used to identify new predictors for M1 at diagnosis. Results: In total, 81 patients with MTC were included for analysis. M1 disease at presentation was found in 27%. Sensitivity and specificity for the current calcitonin cutoff were 90.9% (95% CI, 72.2-97.5) and 47.5% (95% CI, 35.3-60.0), respectively. In multivariable analysis, presence of suspicious lymph nodes on preoperative ultrasound was the strongest predictor (odds ratio [OR] 6.7; 95% CI, 1.3-34.2; Conclusion: To our knowledge, this is the first study investigating the optimal combination of predictors for M1 disease in MTC at diagnosis. Suspicious lymph nodes on ultrasound is the strongest predictor for M1 disease, well exceeding calcitonin levels. Incorporating suspicious lymph nodes and calcitonin into a novel clinical decision tool may optimize M1 detection while reducing unnecessary imaging.

Indexed as

calcitonindiagnosisdistant metastasesimaginglymph nodesmedullary thyroid cancer

Identifiers

PMID41799688
PMCPMC12962234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.